Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

Summary

The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size.

Timeline

Start

2009-06

Primary completion

2011-11

Completion

2011-11

Outcome

Outcome not reported

Stopped: “unable to identify a third subject”

Drugs

Indications